2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology

Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading

Italy undertakes bold measures on transparency by adopting the Pricing and Reimbursement Decree

On Friday, 24 July 2020, Italy officially published the long-anticipated Pricing and Reimbursement Decree in the Gazzetta Ufficiale della Repubblica Italiana setting in motion Italy’s place as the first country to implement the WHO transparency resolution (WHA72.8). In statement before… Continue Reading

WTO TRIPS Council (July 2020): The European Union’s position on the interface of IP and health technologies in the COVID-19 response

On 30 July 2020, the World Trade Organization (WTO) convened a formal meeting of the TRIPS Council. The TRIPS Council held discussions on two COVID-19 related topics: agenda item 3 on IP Measures in the Context of COVID-19 and agenda… Continue Reading

WTO TRIPS Council (July 2020): South Africa’s submission on IP and the Public Interest – Beyond Access to Medicines and Medical Technologies towards a more Holistic Approach to TRIPS Flexibilities

On Friday, 17 July 2020, South Africa submitted a paper to the World Trade Organization (WTO) TRIPS Council entitled, Intellectual Property and the Public Interest: Beyond Access to Medicines and Medical Technologies Towards a More Holistic Approach To TRIPS Flexibilities.… Continue Reading

KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment

On July 7, 2020, Knowledge Ecology International (KEI) submitted comments to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the… Continue Reading

Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy

On July 6, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment submitted joint comments regarding the National Institutes of Health’s (NIH) proposed exclusive license for the development and commercialization of cell therapies for cancer (85 FR 36872).… Continue Reading

The European Parliament calls on the European Commission and the Member States to formally support the COVID-19 Technology Access Pool (C-TAP)

On Friday, 10 July 2020, the European Parliament adopted a resolution entitled, The EU’s public health strategy post-COVID-19, by 526 votes to 105 and 50 abstentions. This resolution paves the way for the creation of a European Health Union and… Continue Reading

KEI receives seven new contracts for COVID 19 research from BARDA and DOD, including five using “Other Transactions Authority” that weaken or eliminate Bayh-Dole and FAR Safeguards

KEI has a number of outstanding requests under the United States Freedom of Information Act (FOIA) for contracts related to biomedical innovations to control or treat the COVID-19 pandemic. On Thursday, June 25, and Friday, June 26, we received a… Continue Reading

Joint Comments on Two NIH Exclusive Licenses to CAR Therapy to Vor Biopharma and Senti Bio

On June 15, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatments (UACT) submitted joint comments to the National Institutes of Health regarding two prospective exclusive patent licenses: “Prospective Grant of an Exclusive Patent License: Development and… Continue Reading